Haleos Labs Limited has disclosed that its promoters and promoter group members did not encumber any shares, directly or indirectly, during the year ended March 31, 2026. The company submitted the annual disclosure to BSE Limited and National Stock Exchange of India Limited, confirming that the total pledged shares across the promoter group remain zero. This indicates that no shares were used as collateral to secure loans or other obligations during the financial year, reflecting a clean capital structure regarding promoter holdings.

The declaration, signed by TVVSN Murthy on behalf of the promoter and promoter groups, detailed the current status of shareholding and encumbrance for all relevant entities. The filing is a mandatory compliance requirement under listing regulations, ensuring transparency regarding the financial leverage of key stakeholders in the company.

Status of Promoter Holdings

The disclosure lists the equity shareholding of each promoter and promoter group member, confirming that none of these holdings are currently pledged. The data covers individual promoters as well as corporate entities within the group.

The document was copied to the members of the Audit Committee and the Company Secretary of Haleos Labs Limited for their records and necessary action.

Haleos Labs Limited reported a net profit of ₹1,777.68 lakh for the financial year ended March 31, 2026, a decline from ₹2,137.08 lakh in the previous year. Revenue from operations for the year stood at ₹30,098.96 lakh, compared to ₹33,337.10 lakh in FY25. The Board of Directors, in its meeting held on May 29, 2026, approved the audited standalone and consolidated financial results and recommended a dividend of ₹1.50 per equity share of ₹10 face value for the year 2025-26, subject to shareholder approval.

Financial Performance

For the quarter ended March 31, 2026, the company reported a net profit of ₹223.46 lakh on revenue from operations of ₹6,338.42 lakh. In the corresponding quarter of the previous year, the net profit was ₹267.51 lakh on revenue of ₹8,542.78 lakh. Total expenses for the year increased to ₹27,721.96 lakh from ₹30,727.55 lakh in the prior year. The statutory auditors, M/s Rambabu & Co., issued an unmodified opinion on the financial results.

Board Decisions and Corporate Actions

The Board approved the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for a further period of five years effective from September 2, 2026, subject to shareholder approval. Additionally, the Board accepted the resignation of Mrs. Sundaramma Patibandla as Independent Director, effective from the close of business hours on May 29, 2026. Consequently, the Audit Committee, Nomination & Remuneration Committee, and Stakeholders' Relationship Committee were reconstituted.

Auditor Appointments and Related Party Transactions

The Board approved the appointment of M/s. Suryanarayana & Suresh, Chartered Accountants, as Statutory Auditors for a period of five years, subject to shareholder approval. M/s Annapragada & Co. was reappointed as Cost Auditors for the year 2026-27. The company disclosed related party transactions for the half year ended March 31, 2026, including transactions with Purogene Labs Private Limited and Mahi Drugs Private Limited.

Key Financial Metrics for FY26